426 related articles for article (PubMed ID: 28008151)
1. Tonsillar CD56brightNKG2A+ NK cells restrict primary Epstein-Barr virus infection in B cells via IFN-γ.
Jud A; Kotur M; Berger C; Gysin C; Nadal D; Lünemann A
Oncotarget; 2017 Jan; 8(4):6130-6141. PubMed ID: 28008151
[TBL] [Abstract][Full Text] [Related]
2. A distinct subpopulation of human NK cells restricts B cell transformation by EBV.
Lünemann A; Vanoaica LD; Azzi T; Nadal D; Münz C
J Immunol; 2013 Nov; 191(10):4989-95. PubMed ID: 24108698
[TBL] [Abstract][Full Text] [Related]
3. Tonsilar NK cells restrict B cell transformation by the Epstein-Barr virus via IFN-gamma.
Strowig T; Brilot F; Arrey F; Bougras G; Thomas D; Muller WA; Münz C
PLoS Pathog; 2008 Feb; 4(2):e27. PubMed ID: 18266470
[TBL] [Abstract][Full Text] [Related]
4. Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56
Lam JKP; Azzi T; Hui KF; Wong AMG; McHugh D; Caduff N; Chan KH; Münz C; Chiang AKS
Front Immunol; 2020; 11():1231. PubMed ID: 32625211
[TBL] [Abstract][Full Text] [Related]
5. Activation of ATR-Chk1 pathway facilitates EBV-mediated transformation of primary tonsillar B-cells.
Mordasini V; Ueda S; Aslandogmus R; Berger C; Gysin C; Hühn D; Sartori AA; Bernasconi M; Nadal D
Oncotarget; 2017 Jan; 8(4):6461-6474. PubMed ID: 28031537
[TBL] [Abstract][Full Text] [Related]
6. Impaired cytotoxic T lymphocyte response to Epstein-Barr virus-infected NK cells in patients with severe chronic active EBV infection.
Tsuge I; Morishima T; Kimura H; Kuzushima K; Matsuoka H
J Med Virol; 2001 Jun; 64(2):141-8. PubMed ID: 11360246
[TBL] [Abstract][Full Text] [Related]
7. The Epstein-Barr Virus Oncogene EBNA1 Suppresses Natural Killer Cell Responses and Apoptosis Early after Infection of Peripheral B Cells.
Westhoff Smith D; Chakravorty A; Hayes M; Hammerschmidt W; Sugden B
mBio; 2021 Dec; 12(6):e0224321. PubMed ID: 34781735
[TBL] [Abstract][Full Text] [Related]
8. Primary immune responses by cord blood CD4(+) T cells and NK cells inhibit Epstein-Barr virus B-cell transformation in vitro.
Wilson AD; Morgan AJ
J Virol; 2002 May; 76(10):5071-81. PubMed ID: 11967323
[TBL] [Abstract][Full Text] [Related]
9. Asymptomatic Primary Infection with Epstein-Barr Virus: Observations on Young Adult Cases.
Abbott RJ; Pachnio A; Pedroza-Pacheco I; Leese AM; Begum J; Long HM; Croom-Carter D; Stacey A; Moss PAH; Hislop AD; Borrow P; Rickinson AB; Bell AI
J Virol; 2017 Nov; 91(21):. PubMed ID: 28835490
[TBL] [Abstract][Full Text] [Related]
10. Distribution and phenotype of Epstein-Barr virus-infected cells in human pharyngeal tonsils.
Hudnall SD; Ge Y; Wei L; Yang NP; Wang HQ; Chen T
Mod Pathol; 2005 Apr; 18(4):519-27. PubMed ID: 15696119
[TBL] [Abstract][Full Text] [Related]
11. Two alternate strategies for innate immunity to Epstein-Barr virus: One using NK cells and the other NK cells and γδ T cells.
Djaoud Z; Guethlein LA; Horowitz A; Azzi T; Nemat-Gorgani N; Olive D; Nadal D; Norman PJ; Münz C; Parham P
J Exp Med; 2017 Jun; 214(6):1827-1841. PubMed ID: 28468758
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus-seropositive children show inhibition of in vitro EBV infection that is associated with CD8+CD57+ T cell enrichment and IFN-γ.
Sohlberg E; Saghafian-Hedengren S; Rasul E; Marchini G; Nilsson C; Klein E; Nagy N; Sverremark-Ekström E
J Immunol; 2013 Dec; 191(11):5669-76. PubMed ID: 24140645
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 15-mediated induction of cytotoxic effector cells capable of eliminating Epstein-Barr virus-transformed/immortalized lymphocytes in culture.
Sharif-Askari E; Fawaz LM; Tran P; Ahmad A; Menezes J
J Natl Cancer Inst; 2001 Nov; 93(22):1724-32. PubMed ID: 11717333
[TBL] [Abstract][Full Text] [Related]
14. Primary CD4+ T-cell responses provide both helper and cytotoxic functions during Epstein-Barr virus infection and transformation of fetal cord blood B cells.
MacArthur GJ; Wilson AD; Birchall MA; Morgan AJ
J Virol; 2007 May; 81(9):4766-75. PubMed ID: 17314172
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus infection negatively impacts the CXCR4-dependent migration of tonsillar B cells.
Ehlin-Henriksson B; Mowafi F; Klein G; Nilsson A
Immunology; 2006 Mar; 117(3):379-85. PubMed ID: 16476057
[TBL] [Abstract][Full Text] [Related]
16. Release of lymphokines after Epstein Barr virus infection in vitro. I. Sources of and kinetics of production of interferons and interleukins in normal humans.
Lotz M; Tsoukas CD; Fong S; Dinarello CA; Carson DA; Vaughan JH
J Immunol; 1986 May; 136(10):3636-42. PubMed ID: 3009608
[TBL] [Abstract][Full Text] [Related]
17. NK cells eliminate Epstein-Barr virus bound to B cells through a specific antibody-mediated uptake.
Alari-Pahissa E; Ataya M; Moraitis I; Campos-Ruiz M; Altadill M; Muntasell A; Moles A; López-Botet M
PLoS Pathog; 2021 Aug; 17(8):e1009868. PubMed ID: 34415956
[TBL] [Abstract][Full Text] [Related]
18. Role of human natural killer cells during Epstein-Barr virus infection.
Münz C
Crit Rev Immunol; 2014; 34(6):501-7. PubMed ID: 25597312
[TBL] [Abstract][Full Text] [Related]
19. Role for early-differentiated natural killer cells in infectious mononucleosis.
Azzi T; Lünemann A; Murer A; Ueda S; Béziat V; Malmberg KJ; Staubli G; Gysin C; Berger C; Münz C; Chijioke O; Nadal D
Blood; 2014 Oct; 124(16):2533-43. PubMed ID: 25205117
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
